Technology Appraisal Committee Meeting Committee C

Minutes: Confirmed

Date and Time: **Wednesday 13 July 2016, 10:00 – 17:00**

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:	1. Chair Professor Andrew Stevens	Present for all notes
	2. David Chandler	
	3. Gail Coster	Present for all notes
	4. Dr Nigel Langford	Present for all notes
	5. Professor Andrea Manca	Present for all notes
	6. Dr Iain Miller	Present for all notes
	7. Vice Chair Professor Eugene Milne	Present for all notes
	8. Dr Anna O'Neill	Present for all notes
	9. Pam Rees	Present for notes 10 to 18
	10. Dr Peter Selby	Present for all notes
	11. Prof Matt Stevenson	Present for all notes
	12. Dr Paul Tappenden	Present for all notes
	13. Robert Walton	Present for all notes
	14. Dr Judith Wardle	Present for all notes

In attendance:

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Dr Frances Sutcliffe	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Stephanie Yates	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Joanne Ekeledo	Administrator, National Institute for Health and Care Excellence	Present for all notes
Ahmed Elsada	Technical Analyst,	Present for notes 05 to 09

	National Institute for Health and Care Excellence	
Nicola Hay	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 05 to 14
Wendy Gidman	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 10 to 14
Henry Edwards	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 15 to 18
Joanne Holden	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 15 to 18

Non-public observers:

Andrea Berardi	ERG representatives	Present for notes 05 to 08
Michelle van Velthoven	ERG representatives	Present for notes 05 to 08
Steve Edwards	ERG representatives	Present for notes 05 to 08
Bram Ramaekers	ERG representatives	Present for notes 10 to 13
Robert Wolff	ERG representatives	Present for notes 10 to 13
Ewen Cummins	ERG representatives	Present for notes 15 to 17
Miriam Brazzelli	ERG representatives	Present for notes 15 to 17
Dr Christopher Fox	Clinical Expert	Present for notes 05 to 08
Dr Karen Linton	Clinical Expert	Present for notes 05 to 08
Professor John Radford	Patient Expert	Present for notes 05 to 08
Jasmine Mikayelyan	Patient Expert	Present for notes 05 to 08
Dr Robert Storey	Clinical Expert	Present for notes 10 to 13
Nazish Khan	Clinical Expert	Present for notes 10 to 13
Nick Hartshorne-Evans	Patient Expert	Present for notes 10 to 13

Helen Powell	NICE observer	Present for all notes
Kate Moring	NICE observer	Present for all notes
Rosie Lovett	NICE observer	Present for all notes
Ross Dent	NICE observer	Present for all notes
Dr Prithwiraj Das	New committee member	Present for all notes

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of brentuximab vedotin for treating CD30-positive Hodgkin's lymphoma, ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction and aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion.

2. Apologies were received from Professor Andrew Renehan, Professor Kathryn Abel, Dr Paul Miller, Professor Rachel Elliott and Professor Stephen O'Brien.

Any other Business

3. None

Appraisal of brentuximab vedotin for treating CD30-positive Hodgkin's lymphoma

Part 1 – Open session

4. The Chair welcomed the invited experts: Dr Christopher Fox, Dr Kim Linton, Professor John Radford and Jasmine to the meeting and they introduced themselves to the Committee.

5. The Chair welcomed company representatives from Takeda to the meeting.

6. The Chair asked all Committee members to declare any relevant interests

    6.1. David Chandler, Gail Coster, Dr Nigel Langford, Professor Andrea Manca, Dr Iain Miller, Vice Chair Professor Eugene Milne, Dr Anna O'Neill, Dr Peter Selby, Prof Matt Stevenson, Dr Paul Tappenden Robert Walton and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of brentuximab vedotin for treating CD30-positive Hodgkin's lymphoma.

7. The Chair asked all NICE Staff to declare any relevant interests.

7.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of brentuximab vedotin for treating CD30-positive Hodgkin's lymphoma.

8. The Chair asked all other invited guests ERG and invited experts, to declare their relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of brentuximab vedotin for treating CD30-positive Hodgkin's lymphoma.

8.2. Dr Christopher Fox has a personal non-specific financial interest he had received travel grants, funding, speaker fees and honorarium from Takeda.

8.2.1. It was agreed that this declaration would not prevent Dr Christopher Fox from participating in this section of the meeting

8.3. Dr Kim Linton has a personal non-specific financial interest she had received honorarium from both Takeda and Jansen.

8.3.1. It was agreed that this declaration would not prevent Dr Kim Linton from participating in this section of the meeting

9. The Chair introduced the lead team, Professor Robert Walton, Dr Paul Tappenden and David Chandler who gave presentations on the clinical effectiveness and cost effectiveness of brentuximab vedotin for treating CD30-positive Hodgkin's lymphoma.

10. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

11. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

12. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

13. The Committee continued to discuss the clinical and cost effectiveness of brentuximab vedotin for treating CD30-positive Hodgkin's.

13.1. The committee decision was based on consensus.

14. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction

Part 1 – Open session

15. The Vice-Chair welcomed the invited experts: Dr Robert Storey, Nazish Khan and Nick Hartshorne-Evans to the meeting and they introduced themselves to the Committee.

16. The Vice-Chair welcomed company representatives from AstraZeneca to the meeting.

17. The Vice-Chair asked all Committee members to declare any relevant interests

    17.1. David Chandler, Gail Coster, Dr Nigel Langford, Professor Andrea Manca, Dr Iain Miller, Dr Anna O'Neill, Dr Peter Selby, Prof Matt Stevenson, Pam Rees, Chair Professor Andrew Stevens, Dr Paul Tappenden, Robert Walton and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction.

18. The Vice-Chair asked all NICE Staff to declare any relevant interests.

    18.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction.

19. The Vice- Chair asked all other invited guests ERG and invited experts to declare their relevant interests.

    19.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction

    19.2. Dr Robert Storey declared a personal non specific financial interest as he has received consultancy fees from AstraZeneca.
    19.2.1. It was agreed that this declaration would not prevent Dr Robert Storey from participating in this section of the meeting

20. The Vice-Chair introduced the lead team, Prof Matt Stevenson, Dr Nigel Langford and David Chandler who gave presentations on the clinical effectiveness and cost effectiveness of ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction.

21. The Vice-Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

22. The Vice-Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

23. The Vice-Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

24. The Committee continued to discuss the clinical and cost effectiveness of ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction

    24.1. The committee decision was based on consensus.

25. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion

Part 1 – Open session

26. The Chair welcomed company representatives from Bayer to the meeting.

27. The Chair asked all Committee members to declare any relevant interests

    27.1. David Chandler, Gail Coster, Dr Nigel Langford, Professor Andrea Manca, Dr Iain Miller, Vice Chair Professor Eugene Milne, Dr Anna O’Neill, Dr Peter Selby, Prof Matt Stevenson, Pam Rees, Dr Paul Tappende, Robert Walton and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion.

28. The Chair asked all NICE Staff to declare any relevant interests.

    28.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the

technologies to be considered as part of the appraisal of aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion.

29. The Chair asked the ERG to declare their relevant interests.

    29.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion.

30. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

31. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

32. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

33. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

34. The Committee continued to discuss the clinical and cost effectiveness of Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion.

    34.1. The committee decision was based on consensus.

35. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

36. Wednesday 10 August 2016, 10:00 – 17:00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.